Waldencast Reports Fiscal Year 2023 Financial Results
April 30, 2024 06:45 ET
|
Waldencast plc.
2023 Net Revenue of $218.1 millionGroup Combined Comparable Revenue of $212.5 million, a 15.3% increase vs 2022Group Combined Adjusted EBITDA of $24.4 million, up from ($8.8) million in 2022 WHITE...
eGain to Announce Fiscal 2024 Third Quarter Financial Results on May 9, 2024
April 30, 2024 06:30 ET
|
eGain Corporation
SUNNYVALE, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- eGain (NASDAQ: EGAN), a knowledge automation platform for customer engagement, will announce its fiscal 2024 third quarter financial results...
Kingsoft Cloud Files Annual Report on Form 20-F for Fiscal Year 2023 and Releases 2023 Environmental, Social and Governance Report
April 30, 2024 06:28 ET
|
Kingsoft Cloud Holdings Limited
BEIJING, April 30, 2024 (GLOBE NEWSWIRE) -- Kingsoft Cloud Holdings Limited (“we,” “Kingsoft Cloud” or the “Company”) (NASDAQ: KC and HKEX: 3896), a leading independent cloud service provider in...
FANHUA Files Annual Report on Form 20-F on April 29, 2024 and Announces Adoption of Semi-annual Financial Results Reporting Schedule
April 30, 2024 06:17 ET
|
Fanhua Inc.
GUANGZHOU, China, April 30, 2024 (GLOBE NEWSWIRE) -- FANHUA Inc. (Nasdaq: FANH) (the “Company” or “FANHUA”), a leading independent technology-driven financial services provider in China, today...
Li Auto Inc. Announces Completion of the Put Right Offer for Its 0.25% Convertible Senior Notes due 2028
April 30, 2024 06:10 ET
|
Li Auto Inc.
BEIJING, China, April 30, 2024 (GLOBE NEWSWIRE) -- Li Auto Inc. (“Li Auto” or the “Company”) (Nasdaq: LI; HKEX: 2015), a leader in China’s new energy vehicle market, today announced that it has...
IN8bio Doses First Patient in Phase 2 Clinical Trial of INB-400 in Newly Diagnosed Glioblastoma
April 30, 2024 06:05 ET
|
IN8bio, Inc
IN8bio Doses First Patient in Phase 2 Clinical Trial of INB-400 in Newly Diagnosed Glioblastoma
MannKind to Proceed With Phase 1 Nintedanib Dpi (Mnkd-201) Study for Pulmonary Fibrotic Diseases
April 30, 2024 06:05 ET
|
MannKind
MannKind announced it will proceed with a Phase 1 study of nintedanib DPI (MNKD-201) for pulmonary fibrotic diseases including IPF.
Iovance Biotherapeutics to Present at Upcoming Conferences
April 30, 2024 06:01 ET
|
Iovance Biotherapeutics, Inc.
SAN CARLOS, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor...
Oaktree Specialty Lending Corporation Announces Permanent Base Management Fee Reduction
April 30, 2024 06:01 ET
|
Oaktree Specialty Lending Corporation
LOS ANGELES, April 30, 2024 (GLOBE NEWSWIRE) -- Oaktree Specialty Lending Corporation (NASDAQ:OCSL) (“OCSL” or the “Company”) today announced a permanent reduction in its base management fee....
H World Group Limited Announces Completion of the Put Right Offer for Its 3.00% Convertible Senior Notes due 2026
April 30, 2024 06:00 ET
|
H World Group Limited
SHANGHAI, China, April 30, 2024 (GLOBE NEWSWIRE) -- H World Group Limited (Nasdaq: HTHT and HKEx: 1179, the “Company” or “H World”), a key player in the global hotel industry, today announced that...